

Charles J Rosser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5292508/publications.pdf>

Version: 2024-02-01

72
papers

2,533
citations

172457

29
h-index

206112

48
g-index

73
all docs

73
docs citations

73
times ranked

3216
citing authors

#	ARTICLE	IF	CITATIONS
1	Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study. <i>Cancer Biomarkers</i> , 2022, 33, 151-157.	1.7	9
2	Clinical Utility of Oncuriaâ„¢, a Multiplexed Liquid Biopsy for the Non-Invasive Detection of Bladder Cancerâ€”A Pilot Study. <i>Diagnostics</i> , 2022, 12, 131.	2.6	4
3	Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors. <i>Nature Communications</i> , 2022, 13, 1487.	12.8	17
4	The dynamic roles of the bladder tumour microenvironment. <i>Nature Reviews Urology</i> , 2022, 19, 515-533.	3.8	24
5	The Molecular Twin platform: a novel machine learning tool for democratization of precision cancer medicine.. <i>Journal of Clinical Oncology</i> , 2022, 40, e13546-e13546.	1.6	0
6	PAI-1 is a potential transcriptional silencer that supports bladder cancer cell activity. <i>Scientific Reports</i> , 2022, 12, .	3.3	3
7	Use of Bladder Sparing Surgery for Muscle Invasive Bladder Cancer by Life Expectancy at Diagnosis. <i>Urology Practice</i> , 2021, 8, 94-99.	0.5	1
8	Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-GuÃ©rin (BCG) for the Treatment of Bladder Cancer. <i>Onc Immunology</i> , 2021, 10, 1912885.	4.6	24
9	Vitamin D receptor upregulates lncRNA TOPORS-AS1 which inhibits the Wnt/ β -catenin pathway and associates with favorable prognosis of ovarian cancer. <i>Scientific Reports</i> , 2021, 11, 7484.	3.3	14
10	Diagnostic performance of Oncuriaâ„¢, a urinalysis test for bladder cancer. <i>Journal of Translational Medicine</i> , 2021, 19, 141.	4.4	24
11	Rationale for Randomized Clinical Trials Investigating the Potential of BCG Vaccination in Preventing COVID-19 Infection. <i>Bladder Cancer</i> , 2021, 7, 121-131.	0.4	0
12	Influencing Factors on the Oncuriaâ„¢ Urinalysis Assay: An Experimental Model. <i>Diagnostics</i> , 2021, 11, 1023.	2.6	5
13	An N-Cadherin 2 expressing epithelial cell subpopulation predicts response to surgery, chemotherapy and immunotherapy in bladder cancer. <i>Nature Communications</i> , 2021, 12, 4906.	12.8	67
14	Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T. , 2021, 9, e002931.		18
15	Case Study of Noni Extract in Men with Very Low-Risk or Low-Risk Prostate Cancer. <i>Hawai'i Journal of Health & Social Welfare</i> , 2021, 80, 242-250.	0.2	0
16	Prognostic Significance of Lymphocyte Infiltration and a Stromal Immunostaining of a Bladder Cancer Associated Diagnostic Panel in Urothelial Carcinoma. <i>Diagnostics</i> , 2020, 10, 14.	2.6	9
17	Analytical validation of ONCURIAâ„¢ a multiplex bead-based immunoassay for the non-invasive bladder cancer detection. <i>Practical Laboratory Medicine</i> , 2020, 22, e00189.	1.3	15
18	Plasminogen activator inhibitor-2 (PAI-2) overexpression supports bladder cancer development in PAI-1 knockout mice in N-butyl-N- (4-hydroxybutyl)-nitrosamine- induced bladder cancer mouse model. <i>Journal of Translational Medicine</i> , 2020, 18, 57.	4.4	8

#	ARTICLE	IF	CITATIONS
19	Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature. <i>Diagnostics</i> , 2019, 9, 166.	2.6	12
20	Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model. <i>Journal of Translational Medicine</i> , 2019, 17, 29.	4.4	18
21	<i>Mycoplasma genitalium</i> Infection and Chronic Inflammation in Human Prostate Cancer: Detection Using Prostatectomy and Needle Biopsy Specimens. <i>Cells</i> , 2019, 8, 212.	4.1	46
22	Monoclonal Antibody against CXCL1 (HL2401) as a Novel Agent in Suppressing IL6 Expression and Tumoral Growth. <i>Theranostics</i> , 2019, 9, 853-867.	10.0	25
23	Diagnostic biomarkers in non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 2009-2016.	2.2	22
24	UroSEEK gene panel for bladder cancer surveillance. <i>Translational Andrology and Urology</i> , 2019, 8, S546-S549.	1.4	6
25	Urinary Protein Markers for the Detection and Prognostication of Urothelial Carcinoma. <i>Methods in Molecular Biology</i> , 2018, 1655, 251-273.	0.9	6
26	Nutritional implications for quality of life in bladder cancer survivors. <i>Translational Andrology and Urology</i> , 2018, 7, S688-S691.	1.4	1
27	Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer. <i>Oncotarget</i> , 2018, 9, 7101-7111.	1.8	21
28	Intravesical ALT-803 for BCG-unresponsive Bladder Cancer – A Case Report. <i>Urology Case Reports</i> , 2017, 14, 15-17.	0.3	18
29	On the brink of extinction: the future of translational physician-scientists in the United States. <i>Journal of Translational Medicine</i> , 2017, 15, 88.	4.4	18
30	Association of MMP-2, RB and PAI-1 with decreased recurrence-free survival and overall survival in bladder cancer patients. <i>Oncotarget</i> , 2017, 8, 99707-99721.	1.8	19
31	A Nomogram Derived by Combination of Demographic and Biomarker Data Improves the Noninvasive Evaluation of Patients at Risk for Bladder Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1361-1366.	2.5	8
32	A multiplex urinary immunoassay for bladder cancer detection: analysis of a Japanese cohort. <i>Journal of Translational Medicine</i> , 2016, 14, 287.	4.4	24
33	A multiplex immunoassay for the non-invasive detection of bladder cancer. <i>Journal of Translational Medicine</i> , 2016, 14, 31.	4.4	34
34	A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer. <i>Oncotarget</i> , 2016, 7, 7253-7267.	1.8	30
35	CXCL1 is elevated in the urine of bladder cancer patients. <i>SpringerPlus</i> , 2015, 4, 610.	1.2	10
36	The Influence of Race on Overall Survival in Patients with Newly Diagnosed Bladder Cancer. <i>Journal of Racial and Ethnic Health Disparities</i> , 2015, 2, 124-131.	3.2	6

#	ARTICLE	IF	CITATIONS
37	Intravesical ALT-803 and BCG Treatment Reduces Tumor Burden in a Carcinogen Induced Bladder Cancer Rat Model; a Role for Cytokine Production and NK Cell Expansion. PLoS ONE, 2014, 9, e96705.	2.5	79
38	Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature. Diagnostic Pathology, 2014, 9, 200.	2.0	30
39	PAI-1 Leads to G1-Phase Cell-Cycle Progression through Cyclin D3/cdk4/6 Upregulation. Molecular Cancer Research, 2014, 12, 322-334.	3.4	42
40	Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer. BMC Cancer, 2014, 14, 86.	2.6	19
41	Urinary Protein Biomarker Panel for the Detection of Recurrent Bladder Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1340-1345.	2.5	57
42	External Validation of a Multiplex Urinary Protein Panel for the Detection of Bladder Cancer in a Multicenter Cohort. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1804-1812.	2.5	44
43	Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors. BMC Cancer, 2014, 14, 310.	2.6	72
44	Simultaneous multi-analyte urinary protein assay for bladder cancer detection. BMC Biotechnology, 2014, 14, 24.	3.3	25
45	Multiplex Protein Signature for the Detection of Bladder Cancer in Voided Urine Samples. Journal of Urology, 2013, 190, 2257-2262.	0.4	42
46	Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection. BMC Urology, 2013, 13, 42.	1.4	26
47	Diagnostic Potential of Urinary α -1-Antitrypsin and Apolipoprotein E in the Detection of Bladder Cancer. Journal of Urology, 2013, , .	0.4	2
48	Targeting Plasminogen Activator Inhibitor-1 Inhibits Angiogenesis and Tumor Growth in a Human Cancer Xenograft Model. Molecular Cancer Therapeutics, 2013, 12, 2697-2708.	4.1	63
49	A Candidate Molecular Biomarker Panel for the Detection of Bladder Cancer. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 2149-2158.	2.5	73
50	Urinary BTA: indicator of bladder cancer or of hematuria. World Journal of Urology, 2012, 30, 869-873.	2.2	59
51	Diagnostic Potential of Urinary α -1-Antitrypsin and Apolipoprotein E in the Detection of Bladder Cancer. Journal of Urology, 2012, 188, 2377-2383.	0.4	35
52	Vascular Endothelial Growth Factor, Carbonic Anhydrase 9, and Angiogenin as Urinary Biomarkers for Bladder Cancer Detection. Urology, 2012, 79, 1185.e1-1185.e6.	1.0	47
53	IL-8 as a urinary biomarker for the detection of bladder cancer. BMC Urology, 2012, 12, 12.	1.4	59
54	Influencing factors on the NMP-22 urine assay: an experimental model. BMC Urology, 2012, 12, 23.	1.4	46

#	ARTICLE	IF	CITATIONS
55	CCL18 in a Multiplex Urine-Based Assay for the Detection of Bladder Cancer. PLoS ONE, 2012, 7, e37797.	2.5	76
56	A Multi-Analyte Assay for the Non-Invasive Detection of Bladder Cancer. PLoS ONE, 2012, 7, e47469.	2.5	84
57	Dual targeting of Bcl-2 and VEGF: A potential strategy to improve therapy for prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 421-429.	1.6	13
58	Urinary Glycoprotein Biomarker Discovery for Bladder Cancer Detection Using LC/MS-MS and Label-Free Quantification. Clinical Cancer Research, 2011, 17, 3349-3359.	7.0	123
59	Today's discoveries to tomorrow's care: cancer biomarkers revisited. Biomarkers in Medicine, 2010, 4, 491-493.	1.4	3
60	Urinary proteomic profiling for diagnostic bladder cancer biomarkers. Expert Review of Proteomics, 2009, 6, 507-514.	3.0	23
61	Utility of serial urinary cytology in the initial evaluation of the patient with microscopic hematuria. BMC Urology, 2009, 9, 12.	1.4	33
62	Bladder Cancer's Associated Gene Expression Signatures Identified by Profiling of Exfoliated Urothelia. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 444-453.	2.5	65
63	Persistent Exposure to Mycoplasma Induces Malignant Transformation of Human Prostate Cells. PLoS ONE, 2009, 4, e6872.	2.5	134
64	Dichloroacetate (DCA) sensitizes both wild-type and over expressing <i>Bcl-2</i> prostate cancer cells in vitro to radiation. Prostate, 2008, 68, 1223-1231.	2.3	168
65	Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts. Molecular Cancer Therapeutics, 2007, 6, 101-111.	4.1	56
66	Bladder Cancer Associated Glycoprotein Signatures Revealed by Urinary Proteomic Profiling. Journal of Proteome Research, 2007, 6, 2631-2639.	3.7	128
67	p37 induces tumor invasiveness. Molecular Cancer Therapeutics, 2005, 4, 1031-1038.	4.1	59
68	Prostate Specific Antigen Bounce Phenomenon After External Beam Radiation for Clinically Localized Prostate Cancer.. Journal of Urology, 2002, 168, 2001-2005.	0.4	80
69	Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. Cancer Gene Therapy, 2002, 9, 687-691.	4.6	66
70	Visualizing superficial human bladder cancer cell growth in vivo by green fluorescent protein expression. Cancer Gene Therapy, 2002, 9, 681-686.	4.6	31
71	Gene therapy for superficial bladder cancer. Expert Review of Anticancer Therapy, 2001, 1, 531-540.	2.4	5
72	Localization of plasminogen activator inhibitor type 1 and 2 in preimplantation mouse development in vitro. Ankara Universitesi Veteriner Fakultesi Dergisi, 0, , .	1.0	0